Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $82

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $94 to $82.